Literature DB >> 21424676

Mineralocorticoid-receptor antagonists in heart failure: a tale of serendipity and success.

Alex Reyentovich1, Stuart D Katz.   

Abstract

Entities:  

Year:  2011        PMID: 21424676     DOI: 10.1007/s11897-011-0055-7

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


× No keyword cloud information.
  16 in total

1.  Aldosterone and spironolactone in heart failure.

Authors:  K T Weber
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

2.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

Review 3.  Reconsidering the roles of the mineralocorticoid receptor.

Authors:  John W Funder
Journal:  Hypertension       Date:  2009-01-12       Impact factor: 10.190

4.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

7.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

8.  Use of aldosterone antagonists in heart failure.

Authors:  Nancy M Albert; Clyde W Yancy; Li Liang; Xin Zhao; Adrian F Hernandez; Eric D Peterson; Christopher P Cannon; Gregg C Fonarow
Journal:  JAMA       Date:  2009-10-21       Impact factor: 56.272

9.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors:  John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.

Authors:  Wenning Qin; Amy E Rudolph; Brian R Bond; Ricardo Rocha; Eric A G Blomme; Joseph J Goellner; John W Funder; Ellen G McMahon
Journal:  Circ Res       Date:  2003-06-05       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.